One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel†
| Autor: | Julinda Mehilli, Helmut Schühlen, Josef Dirschinger, Peter B. Berger, Jurriën M. ten Berg, Franz Dotzer, Franz-Josef Neumann, Christian Volmer, Adnan Kastrati, Claus Schmitt, Albert Schömig, Alban Dibra |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Ticlopidine Abciximab medicine.medical_treatment Myocardial Infarction Disease-Free Survival Immunoglobulin Fab Fragments Double-Blind Method Risk Factors Internal medicine Myocardial Revascularization medicine Humans Angina Unstable Myocardial infarction Angioplasty Balloon Coronary Aged Unstable angina business.industry Antibodies Monoclonal Anticoagulants Percutaneous coronary intervention Middle Aged medicine.disease Clopidogrel Death Sudden Cardiac Treatment Outcome Conventional PCI Cardiology Platelet aggregation inhibitor Female Stents Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors Follow-Up Studies medicine.drug |
| Zdroj: | European Heart Journal. 26:1379-1384 |
| ISSN: | 1522-9645 0195-668X |
| Popis: | Aims In the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Trial, the use of abciximab in patients undergoing percutaneous coronary intervention (PCI) after pretreatment with 600 mg clopidogrel for >2 h was associated with no clinically measurable benefit at 30 days. We assessed whether there was any clinical benefit from abciximab at 1 year follow-up. Methods and results After pre-treatment with 600 mg clopidogrel, a total of 2159 patients undergoing PCI for stable or unstable angina without marked ST-segment shifts or positive biomarkers were randomly assigned to receive abciximab or placebo. The occurrence of the composite endpoint of death, myocardial infarction, or target vessel revascularization was assessed at 1 year after randomization. At 1 year, the composite endpoint occurred in 23.8% of the patients in each group [relative risk (RR), 1.01; 95% confidence interval (CI), 0.85–1.20; P =0.92]. The combined incidence of death and myocardial infarction was 6.0% in the abciximab group and 6.4% in the placebo group (RR, 0.94; 95% CI, 0.67–1.32; P =0.73). The mortality rate was 2.1% in the abciximab group and 2.4% in the placebo group (RR, 0.88; 95% CI, 0.50–1.54; P =0.66). No trend towards clinical benefit was observed with abciximab at 1 year in any subgroup analysed. Conclusion In patients with a low-to-intermediate risk profile undergoing PCI after pre-treatment with a 600 mg clopidogrel for at least 2 h, the use of abciximab offers no additional clinical benefit at 1 year. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|